Form 4: Dianthus CEO Granted 120,000 Stock Options

Dianthus Therapeutics CEO Marino Garcia was granted 120,000 stock options with an exercise price of $39.35, vesting over four years.

Summary

• Marino Garcia, CEO and President of Dianthus Therapeutics, Inc. (DNTH), was granted 120,000 stock options.
• The stock options have an exercise price of $39.35 per share.
• The grant date for these options is September 30, 2025.
• The options will vest in equal monthly installments over four years, commencing after September 30, 2025.
• Vesting is contingent upon Mr. Garcia's continued service to the Issuer.
• The expiration date for these stock options is September 30, 2035.
• Following this transaction, Mr. Garcia beneficially owns 120,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is generally a positive signal, indicating management alignment with shareholder interests and a commitment to long-term value creation. It is a standard compensation practice.

Positives

• The grant of stock options aligns the CEO's financial interests with those of shareholders, incentivizing long-term company performance.
• The significant number of options (120,000) indicates a substantial equity stake for the CEO, reinforcing commitment to the company's future.

Negatives

• Potential future dilution of existing shares if and when these options are exercised, although this is a standard aspect of equity compensation plans.

Future Outlook

The vesting schedule of the stock options over four years after September 30, 2025, indicates an expectation of continued service from the CEO and aligns his long-term incentives with the company's performance.

Industry Context

Executive equity compensation, such as stock option grants, is a common practice across the biotechnology and pharmaceutical industries to attract, retain, and motivate key leadership by aligning their interests with long-term shareholder value creation.

Stakeholder Impact

• Shareholders: The grant aligns the CEO's incentives with shareholder value creation, potentially leading to improved long-term performance. However, it also introduces potential future dilution.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• Marino Garcia's continued service to Dianthus Therapeutics, Inc. is required for the stock options to vest according to the established schedule.

Key Dates

Keywords

Dianthus Therapeutics, DNTH, Marino Garcia, Stock Options, Executive Compensation, Insider Transaction, Equity Grant, CEO